Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Better Therapeutics Inc. (BTTX:NASDAQ), powered by AI.
Better Therapeutics Inc. is currently trading at $0.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Better Therapeutics Inc. on Alpha Lenz.
Better Therapeutics Inc.'s P/E ratio is -0.0.
“Better Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -222.0%.”
Ask for details →Better Therapeutics Inc. is a digital therapeutics company focused on developing prescription digital therapies to treat cardiometabolic diseases. The company integrates cognitive behavioral therapy (CBT) with digital platforms, aiming to provide healthcare solutions that can be prescribed by physicians. A key aspect of its offerings is the utilization of software-based treatment methodologies that are designed to modify behavior and assist in managing conditions such as diabetes, hypertension, and chronic kidney disease. Better Therapeutics operates at the intersection of technology and healthcare, contributing to the growing field of digital health solutions that offer personalized treatment plans without the need for traditional pharmaceuticals. Founded in 2015 and headquartered in San Francisco, California, Better Therapeutics plays a significant role in advancing healthcare innovation by addressing unmet medical needs through digital intervention. Its efforts reflect a shift towards preventive care and the application of behavioral sciences in clinical practice, demonstrating the increasing importance of technology in managing chronic health conditions.
“Better Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -222.0%.”
Ask for details →Better Therapeutics Inc. (ticker: BTTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 54 employees. Market cap is $2,356.
The current price is $0 with a P/E ratio of -0x and P/B of -0x.
ROE is -221.99%.